Showing results (2791-2800 of 6,521) with videos related to

Sort By:
Pageof 653
World Journal of Urology|July 12, 2018
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancerMatteo Ferro, Mihai Dorin Vartolomei, Giorgio Ivan Russo, et al.
World Journal of Urology|July 14, 2018
Special considerations in the urological management of the older spinal cord injury patientLewis W Chan, Tomas L Griebling, Edwin P Arnold, et al.
World Journal of Urology|July 20, 2018
Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision managementJaime O Herrera-Caceres, Antonio Finelli, Michael A S Jewett
World Journal of Urology|July 22, 2018
Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancerChristian Daniel Fankhauser, Cédric Poyet, Stephanie G C Kroeze, et al.
World Journal of Urology|July 25, 2018
The influence of dietary supplementation with cranberry tablets on the urinary risk factors for nephrolithiasisElaine J Redmond, C F Murphy, J Leonard, et al.
World Journal of Urology|November 18, 2005
Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries--immunohistochemical distribution and functional significanceEginhard Waldkirch, Stefan Uckert, Hüseyin Yildirim, et al.
World Journal of Urology|October 17, 2009
Arsenic exposure predicts bladder cancer survival in a US populationRyan C Kwong, Margaret R Karagas, Karl T Kelsey, et al.
World Journal of Urology|November 8, 2005
Influence of a high-oxalate diet on intestinal oxalate absorptionDiana J Zimmermann, Albrecht Hesse, Gerd E von Unruh
World Journal of Urology|December 7, 2005
Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tractStefan Uckert, Christian G Stief, Margit Mayer, et al.
World Journal of Urology|August 18, 2018
Extra-target low-risk prostate cancer: implications for focal high-intensity focused ultrasound of clinically significant prostate cancerA Annoot, J Olivier, P Valtille, et al.
Pageof 653